Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Title of study:
Effects of Ranibizumab to delay or regression non-proliferative diabetic retinopathy(NPDR)
with DME assessed by microaneurysm changes: A pilot study Objectives Diabetic retinopathy
(DR) is a major cause of visual impairment. Anti-vascular endothelial growth factors have
demonstrated therapeutic benefits in diabetic macular edema (DME). We aimed to prospectively
analyze the effects of early intensive treatment using intravitreal ranibizumab (IVR)
injections in nonproliferative diabetic retinopathy patients with macular edema.
Primary objective:
To investigate other efficacy endpoints including other visual acuity, anatomical change in
mild-to-moderate NPDR with DME after intravitreal Ranibizumab injection from baseline through
6 months after treatment.
Secondary objectives:
To compare microvascular changes assessed by microaneurysm counts and perifoveal
non-perfusion area changes and safty in eyes of mild-to-moderate NPDR with DME after
intravitreal Ranibizumab injection from baseline through 6 months after treatment.